livermetastasis pancreascarcinoma
Conditions
Interventions
patients receive either a butyrate enema, placebo or serve as control group.
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Patients undergoing major upper abdominal surgery, i.e. partial hepatectomy or pylorus preserving pancreactico duodenectomy. • Normal liver function, i.e. AST within normal range • Stable western diet • Age > 18 years old • Written informed consent
Exclusion criteria
Exclusion criteria: • Ileo- or colostomy • Parenchymal or inflammatory liver disease • Steroid hormone medication • Lactation, pregnancy • Inflammatory bowel disease • Inborn errors of metabolism (liver enzyme deficiencies) • Excessive drinking (>20 alcoholic consumptions per week) • Smoking • Use of antibiotics during and 3 months prior to the study • Probiotic use during and 2 weeks prior to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| short chain fatty acid concentrations in portal, mesenteric, arterial and hepatic venous blood. From these data we can calculate the role of the liver, large and small intestine and the spleen in SCFA metabolism. | — |
Secondary
| Measure | Time frame |
|---|---|
| nvt | — |
Countries
Netherlands
Outcome results
None listed